Navigation Links
Survival in Medical Technology

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

... significantly prolonged progression-free survival (PFS) compared with FOLFOX alone in the ... "Not only is the improvement in progression-free survival limited to patients with wild-type KRAS tumors, ... primary endpoint of the study is progression-free survival by KRAS status and secondary endpoints include ...

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

... tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose ... Data showed that the projected five-year survival rate is 54% at a median follow up of 4.5 years ... remarkable long-term, progression-free survival after completing the vaccine therapy, even though ...

UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201

... objectives of the study are to evaluate: overall survival (OS), progression-free survival (PFS), the objective response rate (ORR), and to ... benefit rate (CBR), median progression-free survival (PFS) and OS, compared with G/C alone. BSI-201 + ...

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

... growth, but that perifosine also improved the survival of mice bearing neuroblastoma tumors. Moreover, ... children, less than 10% will achieve long-term survival after standard multimodal therapy. ... Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of ...

Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story

... genetic factors as the potential source of the survival gap. "When you look at the dialogue about the issue of race and cancer survival that's gone on over the years," says the paper's ... fact no statistically significant difference in survival based on race for a number of other cancers -- ...

Alfacell Provides Shareholder Update

... we did not meet our primary endpoint of overall survival in our Phase IIIb clinical trial in patients ... who failed a prior chemo therapy. Overall survival was 10.5 months for this group. As we reported in ... requested by the FDA exhibiting a significant survival advantage for those individuals previously ...

Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery

... Blood transfusions may be necessary to ensure survival when a patient is bleeding heavily or has severe ... surgery study, researchers evaluated long-term survival of 9,079 patients at eight hospitals and showed ... Blood Cell Transfusions and Decreased Long-Term survival After Cardiac Surgery. Anesthesia & Analgesia ...

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

... received BSI-201 had a median progression-free survival of 6.9 months and overall survival of 9.2 months compared with 3.3 and 5.7 months, ... alone. The hazard ratios for progression free survival ...

CuraGen Updates CR011-vcMMAE Data at ASCO

... 5.3 months. The median overall progression-free survival (PFS) was 4.4 months. Tumor shrinkage was ... is poor, and studies have shown that the median survival is less than nine months. About Breast ... Despite recent advances in therapy, the median survival of patients with metastatic breast cancer is 2 to ...

Researchers at the Karmanos Cancer Institute in Detroit Discover Feasibility of Chemotherapy Alternative

... study patients over approximately 36 months, the survival rate for 97 percent of those patients was two years and the three-year progression free survival rate was 86 percent. Research was supervised ... experience recurring carcinoma tumors. The survival rate for advanced HNSCC is less than 40 percent. ...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... Overall Response Rate as well as Extends Overall survival vs. Capecitabine + Placebo in Patients with 2nd ... not a primary endpoint in the study, overall survival was analyzed with results as follows: ... + Placebo 16.3 {95% CI (5.3, 17.1)} * survival calculated from date of randomization until date ...

TNFerade(TM) Phase III Data Presented at ASCO

... Md., June 1 /PRNewswire-FirstCall/ -- Overall survival data in locally advanced pancreatic cancer ... the PACT trial. This interim analysis of overall survival was conducted after the 92nd death (one-third of ... to reach maturity, we are encouraged by the survival trend being observed at this point in the trial." ...

Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer

... - Interim median progression-free survival of at least six months By contrast, no ... without the BRAF mutation, and progression-free survival was less than two months, consistent with ... improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 ...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

... significant increase in progression-free survival at three years for women with locally advanced ... (p=0.029) increase in progression-free survival at three years for patients treated with the ... "Lilly continues to look for ways to improve the survival of people living with cancer and fill unmet needs ...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

... Overall Response Rate as well as Extended Overall survival vs. Capecitabine + Placebo in Patients with 2nd ... not a primary endpoint in the study, overall survival was analyzed with results as follows: ... treatment. **As of May 2009, median overall survival in the perifosine + capecitabine patient ...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

... significant improvement in progression-free survival (PFS), the length of time a patient lives without ... P=0.004, Lung Cancer Symptom Scale). Overall survival in both studies showed a positive trend, although ... diagnosed at the advanced stage, when five year survival falls to approximately 15%(6). ...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

... as response rate (RECIST), and progression-free survival (PFS) in RCC patients who failed a prior VEGF ... weeks [95% CI (11.9, 19)]. The median overall survival has not been reached with 33 of 46 patients (72%) ... cancer is confined to the kidney, the five-year survival rate is 60 to 70 percent; but ...

Senesco Announces H1N1 Influenza Survival Test Results in Mice

... ) today reported results of H1N1 mouse influenza survival studies that were conducted in Dr. William ... siRNA against Senesco's Factor 5A gene had a 52% survival rate as opposed to a 14% survival rate for mice that received no treatment or a ...

Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)

... The secondary endpoints of progression-free survival (PFS) and categorical change in FVC were also met ... FVC and secondary endpoints of progression-free survival and categorical change in percent predicted FVC. ... and symptoms increase in severity. The median survival time from diagnosis is two to five years, with a ...

Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

... is designed to detect an improvement in overall survival in patients receiving talactoferrin, and results ... this Phase II trial had a median progression-free survival of 6.4 months, median overall survival of 21.1 months, and a ...

Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials

... Clinical Science program that show real-word survival rates for implantable cardiac device patients ... LATITUDE(R) Patient Management system. Five-year survival rate data for patients using implantable ... system, include: Five-year survival rates for ICD patients of up to 92 percent ...

Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer

... an experimental immunotherapy improved survival in men with metastatic disease, according to new ... Compared to placebo, sipuleucel-T extended median survival by 4.1 months and improved three-year survival by 38 percent. Sipuleucel-T successfully exceeded ...

Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

... - Extended Median survival by 4.1 Months and Increased 3-Year survival by 38 Percent Compared to Placebo - - First ... Cellular Immunotherapy for Cancer to Prolong survival - - Company to Host Webcast at 5:30 pm ET - ...

HeartWare International Clinical Trial Shows 90% Survival at 180 Days

... across 5 participating centers. The data show a survival rate of 90% at 6 months and a survival rate of approximately 86% at 12 months post ... the ISHLT meeting 12 months ago we reported a 90% survival among our initial patient cohort. It is pleasing ...

Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study

... - Anthim Dramatically Improves survival in Animals with Clinical Symptoms of Anthrax ... A single dose of Anthim provided a significant survival benefit (up to 94 percent survival in treated rabbits vs. 0 percent in controls) ...

Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer

... "We believe that picoplatin will provide a survival benefit for SCLC patients who have failed platinum-based therapy consistent with survival data we have previously generated in two ... is event-driven and we expect that the overall survival data from the SPEAR trial will show a ...

Micromet Has Started a New Phase 2 Trial with Adecatumumab in Colorectal Cancer Patients

... Ability of Adecatumumab to Prolong Disease Free survival in High Risk Patients with Liver Metastases ... The primary endpoint will be the disease-free survival rate at one year. "The relapse of ... of their disease. The only chance of long-term survival comes with curative resection of hepatic ...

Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results

... Phase 1 data. Additionally, extended Phase 1 survival data was reported. To view the Multimedia ... Florida." Commenting on extended long-term survival data now available for subjects who participated ... Thompson noted, "There was an improvement in survival for those subjects achieving an objective ...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

... be well tolerated, with a median progression-free survival in responding patients of 10.9 months. Median overall survival still has not been reached now at 17 months. Nine ... Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of ...

A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe

... renal cell carcinoma that can increase overall survival in comparison with Pfizer's Sutent would earn a ... (Metastatic): Axitinib's Improvements in Overall survival will Differentiate it from Current and Emerging Therapies finds that a therapy's effect on overall survival is the attribute that most influences surveyed ...

Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival

... without DCVax(R)-Brain have a median survival of only 14.6 months, and less than 5% of these ... patients have lived longer than the median survival of 14.6 months with existing standard of care ... longer than the median progression free survival of 6.9 months with existing standard of care ...

Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports

... significantly prolonged both disease-free survival and recurrence-free survival. Study details ... survival. Recurrence-free survival, overall survival and bone-mineral density were secondary endpoints. Disease-free survival was defined as the length of time after ...

Implantable Defibrillators Lower Risk of Death in Older Heart Patients

... with reduced heart function. -- This survival benefit applied to patients 75 years and older in ... cardioverter defibrillators (ICDs) can improve survival in patients with heart damage --- even those in ... age 75 or older, they found that the level of survival benefit remained intact. But the benefit ...

New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer

... N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the ... XELOX) significantly improved progression-free survival by investigator assessment compared to ... Head, Medical Affairs, Roche. "With these overall survival data in advanced colorectal cancer, we have ...

RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments

... objective response rate (ORR), progression-free survival (PFS) and overall survival (OS), and to describe the safety profile of ... progression-free at four months. Median overall survival was not attained at the time of evaluation. ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... endpoints included response rate, overall survival and safety. Response rates (the ... versus 26% respectively; p= 0.0085). Overall survival data were not yet mature; a final protocol-specified survival analysis is planned after the occurrence of 485 ...

Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery

... Group (BIG) 1-98 study. The suggested survival benefit from the ITT analysis is important ... these are the first data to suggest a survival benefit for an aromatase inhibitor versus ... For the first time, we are seeing suggested survival benefit with aromatase inhibitor therapy for five ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

... response (PR). The median progression-free survival (PFS) for the 21 patients (70%) who achieved at ... patients are still alive and the median overall survival has not been reached at 16.8 months. Ten ... Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of ...

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

... Data Showed Campath May Lead to Overall survival in Patients with Poor Prognostic Factors ... a poor prognosis including significantly inferior survival compared to other CLL patients. Past studies have ... with Campath resulted in progression free survival (PFS) and ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... Phase III VISTA(1) trial showing continued survival improvement for patients with previously ... prednisone continued to demonstrate a long-term survival advantage for patients with previously untreated ... the impact of subsequent therapy on the overall survival (OS) results. The updated results, which were ...
Other Contents
(Date:7/10/2014)... Ill. , July 9, 2014 ... (EHR), spurred in large part by meaningful use ... health care providers interact with laboratory information. Now, ... in the field of clinical informatics in order ... To address the educational needs of ...
(Date:7/10/2014)... German . An ... a central step of photosynthesis in action for the first ... State University used the world,s most powerful X-ray flashlight at ... of a molecular complex called photosystem II as it splits ... oxygen in earth,s atmosphere. The researchers report their results in ...
(Date:7/10/2014)... megacity, teeming with life too small to be seen. ... bacteria can be found. Now scientists have discovered ... daily cyclesnot unlike the residents of a bustling city ... at the same times., What,s more, it,s not all ... to help them photosynthesize food from inorganic substanceshave been ...
Breaking Biology News(10 mins):New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4Scientists watch photosynthesis in action 2Scientists watch photosynthesis in action 3New research finds ocean's most abundant organisms have clear daily cycles 2New research finds ocean's most abundant organisms have clear daily cycles 3
(Date:7/10/2014)... (PRWEB) July 10, 2014 Thousands ... gather in Copenhagen this July 13-17 to reveal ... the world closer to breakthroughs in dementia science. ... world’s largest conference of its kind. , As ... serves as a catalyst for generating new knowledge ...
(Date:7/10/2014)... York, US (PRWEB) July 10, 2014 ... , Merrill DataSite recently streamed the live webinar ‘Capitalizing ... a discussion from a group of several M&A experts ... seeing in the broader energy transaction marketplace. These experts ... and how the deal market in this sector has ...
(Date:7/10/2014)... CBPartners, a global leader in consulting ... new website. The redesigned site boasts improved navigation ... the firm’s thought pieces, blog posts, and conference presentations. ... showcase our insights, capabilities, and to provide timely updates ... Officer, Cyrus Chowdhury. “An enhanced online presence is ...
(Date:7/10/2014)... Best Drug Rehabilitation , ... family close by during a stay in rehab ... not the process is successful, has launched an ... http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success Stories ... several Best Drug Rehabilitation graduates who wanted to ...
(Date:7/10/2014)... Washington, New York (PRWEB) July 10, 2014 ... firm dedicated to protecting the rights of victims ... couple has brought a lawsuit over allegations that ... her body by a power morcellator used during ... has been filed against Richard Wolf Medical Instruments ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
Other TagsOther Tags